Ampio Provides Update on Results from Pre-IND Enabling Studies [Yahoo! Finance]
Ampio Pharmaceuticals, Inc. (AMPE)
US:NASDAQ Investor Relations:
ampiopharma.com
Company Research
Source: Yahoo! Finance
biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce pain and preserve cartilage in nonclinical models of osteoarthritis of the knee, the pain reduction benefit was not observed in the data from the recent set of preclinical studies which utilized a larger population of animal subjects. "We believe we need to demonstrate a statistically significant improvement in both pain reduction and cartilage protection to support the IND and justify the capital necessary to complete the planned
Show less
Read more
Impact Snapshot
Event Time:
AMPE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPE alerts
High impacting Ampio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPE
News
- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation [Yahoo! Finance]Yahoo! Finance
- Ampio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationPR Newswire